PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2008
CASE
Pierre Fabre ⭐ Case of the Week

Anonymous v Pierre Fabre: representative emails about β€˜oral chemotherapy clinics’ ruled non-promotional (no breach)

Anonymous complaint alleged unsolicited promotional emails to NHS staff about setting up β€˜oral chemotherapy’ clinics without consent or prescribing info. Panel found…

2012
CASE
AUTH/2515/6/12 Merz

AUTH/2515/6/12: Allergan/Director v Merz β€” Bocouture vs Botox β€œComparable efficacy” and β€œ1:1 Clinical Conversion Ratio” (No breach)

Allergan alleged Merz’s FACE conference stand/leavepiece implied Bocouture and Botox were interchangeable/equivalent (1:1 conversion). Panel and Appeal Board held β€œcomparable efficacy” did…

2012
CASE
AUTH/2565/11/12 Boehringer Ingelheim

Boehringer Ingelheim: market research survey invite over-emphasised payments and implied switching incentive (AUTH/2565/11/12, AUTH/2566/11/12, AUTH/2567/11/12)

Three HCPs complained about an NVAF stroke-prevention online survey invite offering Β£70 plus extra Β£5 for β€œSwitched to Pradaxa/Xarelto” forms. Survey wasn’t…

2012
CASE
AUTH/2535/10/12 Pfizer

AUTH/2535/10/12: Patient v Pfizer β€” Champix (varenicline) patient leaflets and seizure warnings (No breach)

A patient alleged Pfizer failed to warn about seizures/convulsions with Champix. PMCPA found UK patient materials reflected the SPC/PIL at the time…

2013
CASE
AUTH/2586/3/13 Ferring Pharmaceuticals

Ferring voluntary admission: uncertified symposium flyers sent to 436 UK delegates (AUTH/2586/3/13)

Ferring’s global office mistakenly mailed two Milan congress symposium flyers to 436 UK delegates. PMCPA ruled both flyers were promotional and uncertified…

2013
CASE
AUTH/2641/9/13 Lundbeck ⭐ Case of the Week

AUTH/2641/9/13: Chief Pharmacist v Lundbeck β€” Cipralex promotional email (no breach)

A chief pharmacist complained about a Cipralex (escitalopram) promotional email sent via a database agency to local prescribers despite non-formulary status. The…

2013
CASE
AUTH/2610/6/13 Tillotts Pharma UK

Tillotts Pharma: β€˜Educational update’ journal supplement ruled disguised promotion and misleading cost/guideline messaging (Octasa) (AUTH/2610/6/13)

A British Journal of Clinical Pharmacy supplement branded as an β€œEducational update” about Octasa was ruled disguised promotion. Multiple misleading/unsubstantiated cost and…

2013
CASE
AUTH/2628/8/13 Chiesi

Chiesi: BJMA β€˜Annual Scientific Meeting’ sponsorship raised concerns over social focus and due diligence (AUTH/2628/8/13)

Anonymous complaint about BJMA meeting sponsorship (Bolton, July 2013). Panel saw event as mainly social with limited science. Chiesi appealed: Clause 19.1…

2013
CASE
AUTH/2644/10/13 Galen

AUTH/2644/10/13: Norgine v Galen β€” Prescribing policy for Laxido Orange (no breach; switch services allegation)

Norgine alleged Galen’s prescribing policy on switching Movicol to Laxido Orange indirectly facilitated a prohibited switch programme. Panel and Appeal Board ruled…

2015
CASE
AUTH/2793/9/15 AstraZeneca

AstraZeneca Forxiga EMIS Web β€˜9 step guide’ ruled misleading; corrective statement and public reprimand (AUTH/2793/9/15)

AstraZeneca’s EMIS Web search guide for identifying patients for Forxiga was ruled misleading and inconsistent with the SPC, with undue weight-loss emphasis…

2015
CASE
Actavis ⭐ Case of the Week

Bayer v Actavis: Levosert leavepiece ruled misleading on breadth of suitability and β€œ25% saving” cost claim

Actavis’ Levosert leavepiece implied broader suitability than Mirena and claimed a β€œ25% saving” on acquisition cost. PMCPA ruled the claims misleading/unsubstantiated and…

2015
CASE
AUTH/2756/5/15 Merck Serono

Merck Serono call-rate targets: pressure for β€œ6 calls/contacts per day” and uncertified field briefings (AUTH/2756/5/15)

Anonymous employee alleged Merck Serono neurology KAMs were pushed to achieve 6 calls/contacts per day. Panel found targets risked inconvenience and Code…

2013
CASE
AUTH/2620/7/13 Sanofi

Sanofi breached an undertaking over a repeat β€œonly once-daily GLP‑1RA” claim in a Nursing Times supplement (AUTH/2620/7/13)

Sanofi was found to have breached a prior PMCPA undertaking after a Nursing Times promotional supplement repeated a very similar β€œonly once-daily…

2014
CASE
AUTH/2725/7/14 Roche Products

AUTH/2725/7/14: Member of the public v Roche – Daily Mirror article about Avastin (No breach)

Complaint alleged Roche instigated a Daily Mirror story promoting off-label Avastin use for brain tumours. Panel found allegations not proven on balance…

2014
CASE
AUTH/2716/5/14 Napp Pharmaceuticals

AUTH/2716/5/14: Napp voluntary admissionβ€”conference sponsorship emails implied inducement

Napp admitted concerns about a rep’s conduct. Panel found no breach on alleged false pretence for an appointment, but ruled breaches where…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training